MASHINIi

Biodexa Pharmaceuticals plc.

BDRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Biodexa Pharmaceuticals Plc is a biopharmaceutical company focused on the development of innovative therapies for unmet medical needs. The company's pipeline includes products in various stages of development, targeting a range of diseases. Biodexa Pharmaceuticals utilizes drug delivery technologies...Show More

Ethical Profile

Mixed.

Biodexa Pharmaceuticals plc presents a mixed ethical profile. The company is fundamentally dedicated to "Better Health for All," developing treatments for Type 1 diabetes and rare brain cancers, utilizing innovative drug delivery platforms like Q-Sphera. However, its "Planet-Friendly Business" efforts show room for improvement; while Scope 2 emissions were 18 tCO₂e in 2023 (down from 25 tCO₂e in 2021), reports suggest no immediate plans for energy efficiency improvements, and there's limited reporting on other environmental metrics. For areas like "Fair Pay & Worker Respect," "Honest & Fair Business," and "Kind to Animals," there is insufficient public evidence to determine a comprehensive ethical score, with critics pointing to a lack of specific data on animal testing policies or employee treatment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Biodexa Pharmaceuticals plc on Better Health for All.

Fair Money & Economic Opportunity

0

Biodexa Pharmaceuticals PLC is a biopharmaceutical company focused on drug development. The 'Fair Money & Economic Opportunity' value assesses activities related to lending, insuring, moving, or storing money, and their impact on financial inclusion and economic opportunity for underserved populations. The company's core business does not involve financial services or products.

1
Therefore, none of the provided articles contain specific, concrete evidence that directly addresses the quantitative thresholds or qualitative criteria for any of the KPIs within this value, which are designed for financial institutions. As such, all KPIs are omitted due to a lack of relevant data.

Fair Pay & Worker Respect

0

No evidence available to assess Biodexa Pharmaceuticals plc on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No specific data related to fair trade, ethical sourcing, supplier audits, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, high-risk materials spend, or supplier diversity spend for Biodexa Pharmaceuticals PLC was found in the provided articles.

1
The reports reviewed either explicitly stated the absence of such data or focused on general corporate governance and financial performance without detailing supply chain practices.

Honest & Fair Business

0

No evidence available to assess Biodexa Pharmaceuticals plc on Honest & Fair Business.

Kind to Animals

0

No evidence available to assess Biodexa Pharmaceuticals plc on Kind to Animals.

No War, No Weapons

0

The provided articles do not contain any specific, concrete data points regarding Biodexa Pharmaceuticals plc's involvement in arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, board oversight of defense, export end-user certificates, lobbying related to arms control, humanitarian procurement compliance, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance transparency, ethical red lines, exposure to controversial weapons, war-related supply chain risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, procurement from conflict-affected areas, or ethical red lines compliance.

1
Both articles explicitly state that no data relevant to the 'No War, No Weapons' value is present.
2
Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

-20

Biodexa Pharmaceuticals reported total Scope 2 and 3 emissions of 21 tCO₂e for 2023.

1
This is an increase from 18 tCO₂e in 2022.
2
The company's environmental impact is described as modest, and it monitors energy efficiency using tonnes of CO2 per employee, but has no immediate plans to improve energy efficiency.
3
The company has been compliant with ISO 9001 since 2014 and implemented new COSHH assessment procedures in 2023.
4
No environmental compliance violations were reported.
5

Respect for Cultures & Communities

0

No specific, quantitative evidence was found in the provided articles to assess Biodexa Pharmaceuticals plc against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles contain general corporate governance information and details about the company's Code of Business Conduct and Ethics, but lack concrete data points related to community engagement, cultural preservation, local employment, or incident management specific to cultural contexts.

1

Safe & Smart Tech

0

No evidence available to assess Biodexa Pharmaceuticals plc on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No evidence available to assess Biodexa Pharmaceuticals plc on Zero Waste & Sustainable Products.

Own Biodexa Pharmaceuticals plc?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.